Commo; Stephane

Patent Applications and Registrations

Patent applications and USPTO patent grants for Commo; Stephane.The latest application filed is for "administration of coumarin, butylated hydroxyanisole and ethoxyquine for the treatment of canities".

Company Profile

0.14.14

Commo; Stephane - Chaville N/A FR
Commo; Stephane - Paris FR

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Administration of coumarin, butylated hydroxyanisole and ethoxyquine for the treatment of canities Grant 8,969,407 - Commo March 3, 2	2015-03-03
Administation of ellagic acid for the treatment of canities Grant 8,895,037 - Commo November 25, 2	2014-11-25
Inhibitors of 15-hydroxyprostaglandin dehydrogenase for stimulating pigmentation of the skin or skin appendages Grant 8,735,445 - Michelet , et al. May 27, 2	2014-05-27
Administration of compounds that increase glutathione levels in the melanocytes for the treatment of canities Grant 8,481,762 - Commo July 9, 2	2013-07-09
Administration Of Coumarin, Butylated Hydroxyanisole And Ethoxyquine For The Treatment Of Canities App 20130149360 - COMMO; Stephane	2013-06-13
Administration of agents mimicking dopachrome tautomerase (TRP-2) activity for protecting hair follicle melanocytes Grant 8,445,004 - Commo , et al. May 21, 2	2013-05-21
Administration of coumarin, butylated hydroxyanisole and ethoxyquine for the treatment of canities Grant 8,344,021 - Commo January 1, 2	2013-01-01
Use Of An Extract Of Punica Granatum For Combating Canities App 20120263812 - Commo; Stephane	2012-10-18
Uses of BNIPXL-beta in premature canities Grant 8,178,293 - Bernard , et al. May 15, 2	2012-05-15
Inhibitors Of 15-hydroxyprostaglandin Dehydrogenase For Stimulating Pigmentation Of The Skin Or Skin Appendages App 20110014250 - MICHELET; JEAN-FRANCOIS ; et al.	2011-01-20
Inhibitors of 15-hydroxyprostaglandin dehydrogenase for stimulating pigmentation of the skin or skin appendages Grant 7,705,041 - Michelet , et al. April 27, 2	2010-04-27
Administration Of Agents Mimicking Dopachrome Tautomerase (trp-2) Activity For Protecting Hair Follicle Melanocytes App 20100074929 - Commo; Stephane ; et al.	2010-03-25
Uses of BNIPXL-Beta in premature canities App 20090275033 - Bernard; Bruno ; et al.	2009-11-05
Administration of agents mimicking DOPAchrome tautomerase (TRP-2) activity for protecting hair follicle melanocytes Grant 7,585,514 - Commo , et al. September 8, 2	2009-09-08
Administration of agents inducing dopachrome tautomerase (TRP-2) expression for protecting hair follicle melanocytes App 20090118203 - Commo; Stephane ; et al.	2009-05-07
Administration of ellagic acid for the treatment of canities App 20080026019 - Commo; Stephane	2008-01-31
Administration of coumarin, butylated hydroxyanisole and ethoxyquine for the treatment of canities App 20080026018 - Commo; Stephane	2008-01-31
Administration of 3H-1, 2-dithiole-3-thione, anethole dithiolethione, sulforaphane, phenethyl isothiocyanate, 6-(methylsulfinyl)hexyl isothiocyanate and allyl isothiocyanate for the treatment of canities App 20080027129 - Commo; Stephane	2008-01-31
Administration of compounds that increase glutathione levels in the melanocytes for the treatment of canities App 20080014229 - Commo; Stephane	2008-01-17
Inhibitors of 15-hydroxyprostaglandin dehydrogenase for stimulating pigmentation of the skin or skin appendages App 20060034786 - Michelet; Jean-Francois ; et al.	2006-02-16
Administration of agents inducing DOPAchrome tautomerase (TRP-2) expression for protecting hair follicle melanocytes App 20050208086 - Commo, Stephane ; et al.	2005-09-22
Administration of agents mimicking dopachrome tautomerase (TRP-2) activity for protecting hair follicle melanocytes App 20050186233 - Commo, Stephane ; et al.	2005-08-25

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.